– Pivotal clinical validation data for Percepta Nasal Swab test in early lung cancer detection –
– New data demonstrating ability of Decipher Prostate test to identify high metastasis risk in African American men –
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company with a presence in seven of the top ten cancers in the United States, announced today that six abstracts for its genomic tests in lung, prostate and thyroid cancers will be presented at the 2021 ASCO Annual Meeting, which will be held virtually June 4-8, 2021.
The accepted abstracts include pivotal clinical validation data for Veracyte’s Percepta Nasal Swab. This first-of-its-kind, non-invasive test will help physicians determine which patients with lung nodules found on CT scans are at low risk for cancer and can be safely directed to routine monitoring without fear of missing a cancer and which patients should undergo further, including potentially more-aggressive, clinical work-up. Veracyte plans to introduce the nasal swab-based genomic test in the second half of 2021, as part of the company’s comprehensive lung cancer portfolio.
“We are thrilled with the compelling data that will be presented at ASCO, which reflect our tests’ ability to positively impact patient care in a range of major cancers,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We are particularly excited about the opportunity in lung cancer, where early detection can save lives, but where distinguishing between cancerous and benign lung nodules is often challenging and can lead to missed cancers or unnecessary procedures. We believe our Percepta Nasal Swab test is going to be a game-changer for patients being evaluated for lung cancer.”
Among other Veracyte highlights, researchers will share prospective validation data for the Decipher Prostate test, demonstrating the genomic test’s ability to predict aggressive prostate cancers among African American men as compared to the use of clinical factors alone.
Below are details of the Veracyte abstracts accepted for presentation at ASCO. All posters will be available to meeting registrants on demand beginning June 4, 2021, at 9:00 a.m. EDT.
Title: Early candidate nasal swab classifiers developed using machine learning and whole transcriptome sequencing may improve early lung cancer detection.
(Title of poster to be presented: A validated nasal swab classifier developed using machine learning and whole transcriptome sequencing may improve early lung cancer detection.)
Abstract #: 8551
First Author: Peter Mazzone, M.D., M.P.H., Cleveland Clinic
Title: A prospective Validation of the genomic classifier defines high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study. (oral presentation)
Abstract #: 5005
First Author: Kosj Yamoah, M.D., Ph.D., Moffitt Cancer Center
Time:June 8, 2021, 8:00-11:00 a.m. EDT
Title: The impact of Percepta Genomic Sequencing Classifier (GSC) on clinical decision making in patients with a high- risk lung nodule. (poster presentation)
Abstract #: 8549
First Author: Sonali Sethi, M.D., Cleveland Clinic
Title: Validation of the Decipher Genomic Classifier (GC) in SAKK 09/10: A Phase III Randomized Trial of Dose-Escalated Salvage Radiotherapy (SRT) after Radical Prostatectomy (RP). (poster presentation)
Abstract #: 5010
First Author: Alan Dal Pra, M.D., University of Miami Health System
Title: NTRK, RET, BRAF, and ALK Fusions in Thyroid Fine-Needle Aspirates (FNAs). (poster presentation)
Abstract #: 6083
First Author: Lori J. Wirth, M.D., Massachusetts General Hospital
Title: Detection of actionable molecular alterations through combined DNA/RNA molecular profiling of biopsies collected in early stage lung cancer at time of diagnosis. (online abstract)
Abstract #: e20546
First Author: Joshua Babiarz, Ph.D., Veracyte
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.